Should You Buy Johnson & Johnson Before It Splits?

Motley Fool2021-11-15

The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

leeWT
2021-11-15
leeWT
Why not
- woonws:
  Though question is when
lololol13
2021-11-15
lololol13
Hard to say
htht
2021-11-15
htht
When split, does it become Lil Johnson and Big Johnson?
- woonws:
  [笑哭]
- leeWT:
  Haha 👍
Mtan23
2021-11-15
Mtan23
Good read
RoyNg
2021-11-15
RoyNg
👍🏻
ojxp
2021-11-15
ojxp
Like and comment please
- edelyu:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2183024251?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-11-15 20:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2183024251","market":"us","top_or_hot":-1,"title":"Should You Buy Johnson & Johnson Before It Splits?","media":"Motley Fool","content":"<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">网页链接</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","article_id":"2183024251","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","pubTimestamp":1636978818,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"JNJ":"强生"},"translate_title":"你应该在强生分裂前买下它吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":0.9},"content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":873730205,"gmtCreate":1636985608189,"gmtModify":1636985610521,"author":{"id":"3581563058003710","authorId":"3581563058003710","name":"leeWT","avatar":"https://static.tigerbbs.com/49e0521f4fb5a74a66948df0eddb1c8b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581563058003710","authorIdStr":"3581563058003710"},"htmlText":"Why not","listText":"Why not","text":"Why not","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873730205","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6588617,"gmtCreate":1636988796960,"gmtModify":1636988797071,"authorId":3581999478634265,"author":{"id":3581999478634265,"idStr":"3581999478634265","authorId":3581999478634265,"name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":873730205,"type":1,"supId":0,"prevId":0,"content":"Though question is <u>when</u>","text":"Though question is <u>when</u>","html":"Though question is <u>when</u>"}],"langContent":"CN"},{"id":873705361,"gmtCreate":1636984127625,"gmtModify":1636984127731,"author":{"id":"3583916713249739","authorId":"3583916713249739","name":"lololol13","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3583916713249739","authorIdStr":"3583916713249739"},"htmlText":"Hard to say","listText":"Hard to say","text":"Hard to say","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873705361","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":873441540,"gmtCreate":1636981354181,"gmtModify":1636981591145,"author":{"id":"3574990061555881","authorId":"3574990061555881","name":"htht","avatar":"https://static.tigerbbs.com/3db2a624bd21108fb0def4f8b401d45a","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3574990061555881","authorIdStr":"3574990061555881"},"htmlText":"When split, does it become Lil Johnson and Big Johnson?","listText":"When split, does it become Lil Johnson and Big Johnson?","text":"When split, does it become Lil Johnson and Big Johnson?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/873441540","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6588615,"gmtCreate":1636988782441,"gmtModify":1636988782477,"authorId":3581999478634265,"author":{"id":3581999478634265,"idStr":"3581999478634265","authorId":3581999478634265,"name":"woonws","avatar":"https://static.tigerbbs.com/f26ed1a10ee84ab97229aad191ef3133","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":873441540,"type":1,"supId":0,"prevId":0,"content":"[笑哭]","text":"[笑哭]","html":"[笑哭]"},{"id":6587766,"gmtCreate":1636985624328,"gmtModify":1636985624358,"authorId":3581563058003710,"author":{"id":3581563058003710,"idStr":"3581563058003710","authorId":3581563058003710,"name":"leeWT","avatar":"https://static.tigerbbs.com/49e0521f4fb5a74a66948df0eddb1c8b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":873441540,"type":1,"supId":0,"prevId":0,"content":"Haha 👍","text":"Haha 👍","html":"Haha 👍"}],"langContent":"CN"},{"id":873449432,"gmtCreate":1636981044369,"gmtModify":1636981234940,"author":{"id":"3579572647008782","authorId":"3579572647008782","name":"Mtan23","avatar":"https://static.tigerbbs.com/21a2ddfc414d0d3eab50e895e776bf23","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3579572647008782","authorIdStr":"3579572647008782"},"htmlText":"Good read&nbsp;","listText":"Good read&nbsp;","text":"Good read","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873449432","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":873455346,"gmtCreate":1636980646199,"gmtModify":1636980646549,"author":{"id":"3564661312753196","authorId":"3564661312753196","name":"RoyNg","avatar":"https://static.tigerbbs.com/bf41d7936716f6403b3d1ad4dcbb9ca7","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3564661312753196","authorIdStr":"3564661312753196"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873455346","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":873458643,"gmtCreate":1636980442483,"gmtModify":1636980443299,"author":{"id":"3581477238019949","authorId":"3581477238019949","name":"ojxp","avatar":"https://static.tigerbbs.com/f1cc2cda3ae5a57a5a3b43f6c0c4e93e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581477238019949","authorIdStr":"3581477238019949"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/873458643","repostId":2183024251,"repostType":4,"repost":{"id":"2183024251","pubTimestamp":1636978818,"share":"https://www.laohu8.com/m/news/2183024251?lang=&edition=full","pubTime":"2021-11-15 20:20","market":"us","language":"en","title":"Should You Buy Johnson & Johnson Before It Splits?","url":"https://stock-news.laohu8.com/highlight/detail?id=2183024251","media":"Motley Fool","summary":"The world's largest drugmaker is splitting in two, but what does that mean for shareholders?","content":"<p>The world's largest healthcare company is about to get a little smaller.&nbsp;Recently, <b>Johnson &amp; Johnson</b> (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.</p>\n<p>If you've been considering this dividend-paying stock for <a href=\"https://laohu8.com/S/AONE.U\">one</a> reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.</p>\n<h2>Consumer health just doesn't fit</h2>\n<p>Johnson &amp; Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.</p>\n<p>Johnson &amp; Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.</p>\n<p>In 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.</p>\n<h2>Where the growth is</h2>\n<p>The 7% growth rate J&amp;J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.</p>\n<table border=\"1\">\n <tbody>\n  <tr>\n   <th>Operating Segment</th>\n   <th>2016 Revenue</th>\n   <th>Q3 2021 Revenue Annualized</th>\n   <th>5-Year Annual Growth Rate</th>\n  </tr>\n  <tr>\n   <td>Consumer</td>\n   <td>$13.3 billion</td>\n   <td>$14.8 billion</td>\n   <td>2.2%</td>\n  </tr>\n  <tr>\n   <td>Medical Devices</td>\n   <td>$25.1 billion</td>\n   <td>$26.6 billion</td>\n   <td>1.2%</td>\n  </tr>\n  <tr>\n   <td>Pharmaceuticals</td>\n   <td>$33.5 billion</td>\n   <td>$52.0 billion</td>\n   <td>9.2%</td>\n  </tr>\n </tbody>\n</table>\n<p>Data source: Johnson &amp; Johnson.</p>\n<p>It's no wonder, Johnson &amp; Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .</p>\n<p>Contributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.</p>\n<h2>Looking ahead</h2>\n<p>If you're interested in buying shares of Johnson &amp; Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.</p>\n<p>Shares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.</p>\n<p>At recent prices, Johnson &amp; Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.</p>\n<p>Johnson &amp; Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.</p>\n<p>This dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson &amp; Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Should You Buy Johnson & Johnson Before It Splits?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShould You Buy Johnson & Johnson Before It Splits?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-15 20:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.fool.com/investing/2021/11/15/should-you-buy-johnson-johnson-before-it-splits/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2183024251","content_text":"The world's largest healthcare company is about to get a little smaller. Recently, Johnson & Johnson (NYSE:JNJ) told investors it would spin off its consumer health business into a separate new company.\nIf you've been considering this dividend-paying stock for one reason or another, the impending spinoff isn't anything to worry about. In fact, it makes the stock significantly more attractive. Here's a closer look at the company's plans so you can see why.\nConsumer health just doesn't fit\nJohnson & Johnson is a sprawling conglomerate with over a hundred separate subsidiaries divided into three operating segments: Pharmaceuticals, medical devices, and consumer health. Janssen, the company's pharmaceutical business is the largest and fastest-growing subsidiary of all. Pharmaceutical sales growth has outpaced the diverse medical-device segment but the company wants to keep these two segments together. That's because convincing physicians to order knee replacement gear isn't all that different from convincing physicians to prescribe a new cancer therapy.\nJohnson & Johnson practically created the consumer healthcare business over 130 years ago, so cleaving it is going to feel weird at first. Once the dust settles, though, the spinoff will most likely work out well for investors.\nIn 2021, the consumer health segment is expected to record around $15 billion in revenue, a gain of roughly 7% over 2020. The still-unnamed new consumer health company will hit the ground running with 20 different brands generating over $150 million in annual sales.\nWhere the growth is\nThe 7% growth rate J&J expects to report for topline consumer health segment revenue this year is pretty good. Unfortunately, comparisons to 2020, when people shopped considerably less, are a little misleading.\n\n\n\nOperating Segment\n2016 Revenue\nQ3 2021 Revenue Annualized\n5-Year Annual Growth Rate\n\n\nConsumer\n$13.3 billion\n$14.8 billion\n2.2%\n\n\nMedical Devices\n$25.1 billion\n$26.6 billion\n1.2%\n\n\nPharmaceuticals\n$33.5 billion\n$52.0 billion\n9.2%\n\n\n\nData source: Johnson & Johnson.\nIt's no wonder, Johnson & Johnson wants to focus on pharmaceutical sales. Over the past five years, pharmaceutical sales have increased at an impressive 9.2% annual growth rate. Over the same period, the company's other two segments struggled just to keep moving in the right direction. .\nContributions from the high-margin pharmaceutical segment also have a much stronger impact on the bottom line. Adjusted income before taxes from the pharmaceutical segment worked out to $5.7 billion in the third quarter. Pre-tax profits from medical devices and consumer health came in at $1.7 billion and $0.9 billion respectively.\nLooking ahead\nIf you're interested in buying shares of Johnson & Johnson before they become two, you have plenty of time to think it over. The company is targeting the completion of the planned separation in 18 to 24 months.\nShares of both new companies will initially have smaller payouts but don't let that bother you. Dividend payouts for both new stocks are expected to add up to the same amount shareholders receive ahead of the split.\nAt recent prices, Johnson & Johnson shares offer a juicy 3.1% yield and investors can expect a much larger yield on their original investment down the road. The company is a dividend aristocrat that hasn't gone a whole year without raising its payout since JFK was in office.\nJohnson & Johnson's dividend program is on such solid footing that steady raises in the years ahead shouldn't be a problem. Over the past 12 months, the company used just 42% of the free cash flow generated by operations to make dividend payments.\nThis dividend-paying healthcare stock might not be perfect for every investor, especially those willing to take high risks in return for a shot at huge gains. While I wouldn't expect Johnson & Johnson to outperform the broad market by much, investors can reasonably expect two dividend payments that grow steadily for many years to come.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6586669,"gmtCreate":1636980506204,"gmtModify":1636980506309,"authorId":3582016604911088,"author":{"id":3582016604911088,"idStr":"3582016604911088","authorId":3582016604911088,"name":"edelyu","avatar":"https://static.tigerbbs.com/092df2b4df4fa72903ef644a702141fe","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":873458643,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":83,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2183024251"}